Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

843.60 +5.40 (+0.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance. 
Via Benzinga
Regeneron Earnings Top Views For Biotech Giant
Shares of the biotech giant have been in a sharp slide. 
Via Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today
Via Benzinga
A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
Via Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
Market Whales and Their Recent Bets on REGN Options
Via Benzinga
What the Options Market Tells Us About Regeneron Pharmaceuticals
Via Benzinga
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
Via Benzinga
A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals
Via Benzinga
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients. 
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
One of these players has split its stock in the past. The other one hasn't. 
Via The Motley Fool
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared. 
Via Benzinga
Seagate To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Market Whales and Their Recent Bets on REGN Options
Via Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Via Benzinga
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing health risks. Regeneron is investigating therapies to offset these effects... 
Via Benzinga
Should You Buy the Dip on This Top Growth Stock?
The biotech needs to overcome an issue most drugmakers face at some point. 
Via The Motley Fool
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio? 
Via Benzinga
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
The S&P 500 hit record highs, fueled by Micron and Chinese stimulus. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3... 
Via Benzinga
Exposures Product Safety
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD. 
Via Investor's Business Daily
Exposures Product Safety
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.